Does Semaglutide Contain Gluten — and Is It Safe with Coeliac Disease?

The misconception worth clearing up

A lot of people arrive at this question after reading that some injectable medicines use certain stabilisers or fillers derived from plant or grain sources. It is a reasonable thing to check. The short answer is that semaglutide itself is a peptide (a chain of amino acids synthesised in a laboratory) and the excipients used in Wegovy's formulation are not wheat-derived. Gluten is a protein found in wheat, rye and barley; none of those appear in the published Wegovy injection SmPC.

That said, "it's probably fine" is not the standard a person with coeliac disease should accept from a webpage. The gold standard is the current Summary of Product Characteristics. You can find it by searching the product name on the electronic Medicines Compendium, which holds the manufacturer-verified ingredient lists for UK-licensed products. If anything has changed in a recent manufacturing update, that is where it will appear first.

One thing our prescribers hear fairly regularly: people who have been managing coeliac disease for years become understandably cautious about any new medicine, especially one they will take weekly for months. If you want a thorough answer to whether semaglutide is gluten free, including what the formulation data actually shows, that dedicated page works through the evidence in full. That caution is sensible, not excessive. Worth checking.

Semaglutide's ingredients in plain terms

The Wegovy subcutaneous injection (semaglutide 0.25mg to 2.4mg per dose) contains semaglutide as the active substance, with a short list of excipients: disodium phosphate dihydrate, propylene glycol, phenol, and water for injections. No lactose, no starch, no wheat derivatives. The NHS semaglutide medicines page notes the main ingredients in patient-friendly terms and flags that you should tell your prescriber about any allergies or intolerances before starting.

The newer oral format (Wegovy tablets) uses the same semaglutide molecule co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that allows the peptide to survive the stomach environment. Tablet formulations typically include additional excipients such as microcrystalline cellulose, sodium stearyl fumarate and hydroxypropyl cellulose. None of these are gluten-containing by their established pharmacopoeial specifications, but as with any tablet, anyone with a diagnosed sensitivity should review the full PIL. The oral format has the additional practical point that it is taken on an empty stomach first thing in the morning, which can interact with breakfast timing for people who manage coeliac disease partly through meal planning, worth mentioning to your prescriber.

For a fuller picture of what Wegovy's formulation includes, the full ingredients breakdown goes through each component in detail.

Coeliac disease, GI side effects, and telling your prescriber

Here is the nuance that matters most for someone with coeliac disease: semaglutide commonly causes gastrointestinal side effects, particularly in the early weeks. Nausea, loose stools, bloating and abdominal discomfort are the most frequently reported. For most people these settle within a few weeks as the body adjusts. For someone whose gut is already managing the aftermath of coeliac disease (or who is still working towards full mucosal recovery) these overlapping symptoms can be harder to interpret. Is the nausea from the medicine or a dietary slip? Is the diarrhoea a dose-related effect or a gluten reaction?

That ambiguity does not mean semaglutide is unsuitable for people with coeliac disease (there is no contraindication in the SmPC) but it does mean your prescriber should know your full picture before you start. If you are considering private treatment, the semaglutide overview covers how it works and what the clinical assessment involves. A prescriber who knows about your coeliac diagnosis can help you establish a clear baseline and know what to attribute to what.

If you experience severe or persistent abdominal pain that radiates to your back, seek medical attention promptly, this is unrelated to gluten but is the symptom pattern the MHRA highlights in its guidance on GLP-1 medicines and pancreatitis risk, which affects a small number of patients.

Wegovy as a licensed weight-loss medicine, and the consultation route

Wegovy is a prescription-only medicine licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 and above alongside a weight-related health condition. Semaglutide is the active ingredient across both Wegovy (weight management) and Ozempic (type 2 diabetes), they are the same molecule at different licensed doses and in different clinical contexts, as the Ozempic and semaglutide explainer sets out clearly. For weight management, Wegovy is the relevant licensed UK product; Ozempic is not licensed for that purpose.

If you want to understand the broader landscape of semaglutide-containing medicines available in the UK, the guide to medicines containing semaglutide maps that out. Cost is a separate consideration for many people; a realistic look at what private treatment involves is covered on the Wegovy pricing page.

If you have coeliac disease and are considering whether Wegovy is right for you, the best starting point is a clinical conversation. At nume, a real prescriber (not an automated triage system) reads every consultation the same day it is submitted. Check your eligibility and put your full medical history in front of someone qualified to assess it.